Literature DB >> 21316602

Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma.

Jin Hou1, Li Lin, Weiping Zhou, Zhengxin Wang, Guoshan Ding, Qiongzhu Dong, Lunxiu Qin, Xiaobing Wu, Yuanyuan Zheng, Yun Yang, Wei Tian, Qian Zhang, Chunmei Wang, Qinghua Zhang, Shi-Mei Zhuang, Limin Zheng, Anmin Liang, Wenzhao Tao, Xuetao Cao.   

Abstract

The full scale of human miRNome in specific cell or tissue, especially in cancers, remains to be determined. An in-depth analysis of miRNomes in human normal liver, hepatitis liver, and hepatocellular carcinoma (HCC) was carried out in this study. We found nine miRNAs accounted for ∼88.2% of the miRNome in human liver. The third most highly expressed miR-199a/b-3p is consistently decreased in HCC, and its decrement significantly correlates with poor survival of HCC patients. Moreover, miR-199a/b-3p can target tumor-promoting PAK4 to suppress HCC growth through inhibiting PAK4/Raf/MEK/ERK pathway both in vitro and in vivo. Our study provides miRNomes of human liver and HCC and contributes to better understanding of the important deregulated miRNAs in HCC and liver diseases.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21316602     DOI: 10.1016/j.ccr.2011.01.001

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  329 in total

1.  Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1.

Authors:  Chan Gyu Lee; Young Woo Kim; Eun Hyun Kim; Zhipeng Meng; Wendong Huang; Se Jin Hwang; Sang Geon Kim
Journal:  Gastroenterology       Date:  2012-01-18       Impact factor: 22.682

Review 2.  MicroRNAs in liver disease.

Authors:  Xin Wei Wang; Niels H H Heegaard; Henrik Orum
Journal:  Gastroenterology       Date:  2012-04-11       Impact factor: 22.682

3.  Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma.

Authors:  Ya-Hui Huang; Kwang-Huei Lin; Hua-Chien Chen; Ming-Ling Chang; Chao-Wei Hsu; Ming-Wei Lai; Tse-Ching Chen; Wei-Chen Lee; Yi-Hsin Tseng; Chau-Ting Yeh
Journal:  PLoS One       Date:  2012-05-22       Impact factor: 3.240

Review 4.  Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.

Authors:  Yang-Guang Shao; Ke Ning; Feng Li
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

Review 5.  Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.

Authors:  Kerstin Schütte; Christian Schulz; Alexander Link; Peter Malfertheiner
Journal:  World J Hepatol       Date:  2015-02-27

6.  Deregulation of microRNA expression in peripheral blood mononuclear cells from patients with HCV-related malignancies.

Authors:  Alessia Piluso; Laura Gragnani; Elisa Fognani; Elena Grandini; Monica Monti; Cristina Stasi; Elisabetta Loggi; Marzia Margotti; Fabio Conti; Pietro Andreone; Anna Linda Zignego
Journal:  Hepatol Int       Date:  2015-08-14       Impact factor: 6.047

7.  Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Giacomo Diaz; Marta Melis; Ashley Tice; David E Kleiner; Lopa Mishra; Fausto Zamboni; Patrizia Farci
Journal:  Int J Cancer       Date:  2013-03-16       Impact factor: 7.396

8.  Fibrogenic Signaling Is Suppressed in Hepatic Stellate Cells through Targeting of Connective Tissue Growth Factor (CCN2) by Cellular or Exosomal MicroRNA-199a-5p.

Authors:  Li Chen; Ruju Chen; Victoria M Velazquez; David R Brigstock
Journal:  Am J Pathol       Date:  2016-09-21       Impact factor: 4.307

9.  MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation.

Authors:  Ruifang Wu; Jinrong Zeng; Jin Yuan; Xinjie Deng; Yi Huang; Lina Chen; Peng Zhang; Huan Feng; Zixin Liu; Zijun Wang; Xiaofei Gao; Haijing Wu; Honglin Wang; Yuwen Su; Ming Zhao; Qianjin Lu
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

10.  Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.

Authors:  Bin Xiao; Yu Wang; Wei Li; Megan Baker; Jian Guo; Kelly Corbet; Ephraim L Tsalik; Qi-Jing Li; Scott M Palmer; Christopher W Woods; Zhiguo Li; Nelson J Chao; You-Wen He
Journal:  Blood       Date:  2013-09-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.